Key Points
- Insider sale: Director Los Pinos Elisabet De sold 16,928 shares on Jan. 20 at an average of $4.86 for a total of $82,270.08, trimming her stake by 3.57% to 457,463 shares (≈$2.22M); she also sold 9,049 shares on Oct. 29 at $6.35.
- Company outlook and ownership: Aura Biosciences is a clinical‑stage biopharma with a market cap of about $315.6M, a negative P/E, and a consensus analyst rating of "Moderate Buy" with a $20.50 average target; institutional investors hold roughly 96.75% of the stock.
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 16,928 shares of the company's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $4.86, for a total value of $82,270.08. Following the transaction, the insider directly owned 457,463 shares in the company, valued at approximately $2,223,270.18. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Los Pinos Elisabet De also recently made the following trade(s):
- On Wednesday, October 29th, Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock. The shares were sold at an average price of $6.35, for a total value of $57,461.15.
Aura Biosciences Price Performance
Shares of AURA stock opened at $4.97 on Wednesday. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $8.27. The stock's fifty day moving average price is $5.74 and its 200 day moving average price is $6.13. The company has a market cap of $315.60 million, a price-to-earnings ratio of -2.56 and a beta of 0.46.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.06. As a group, equities research analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.
Hedge Funds Weigh In On Aura Biosciences
Hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new position in Aura Biosciences during the 1st quarter worth approximately $137,000. Atria Investments Inc acquired a new stake in shares of Aura Biosciences in the second quarter worth $190,000. Levin Capital Strategies L.P. raised its holdings in shares of Aura Biosciences by 9.9% during the second quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company's stock worth $9,362,000 after purchasing an additional 134,792 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Aura Biosciences by 5.9% during the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company's stock worth $14,653,000 after purchasing an additional 130,221 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in Aura Biosciences during the second quarter valued at $76,000. Institutional investors and hedge funds own 96.75% of the company's stock.
Analysts Set New Price Targets
AURA has been the subject of a number of recent analyst reports. Evercore ISI began coverage on shares of Aura Biosciences in a research note on Tuesday, November 25th. They issued an "outperform" rating for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $20.50.
View Our Latest Analysis on Aura Biosciences
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
